Disseminated Tuberculosis with Hemophagocytic Lymphohistiocytosis (HLH)

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4686-4686
Author(s):  
Suparna Ajit Rao ◽  
Tarun K. Dutta ◽  
Rakesh V Naik ◽  
Aishwarya Krishnamurthy ◽  
Vinod K. Viswanath

Abstract Abstract 4686 A 38 year old woman presented with high grade fever and jaundice for one month. Patient also had reduced appetite and loss of weight for the same period. On examination, patient had significant pallor, icterus and pedal edema. Ultrasonogram showed enlarged liver (20 cms) and enlarged spleen (17.2 cms). Patient was empirically treated for malaria. Her subsequent investigations revealed Hb 35g/dl, total leucocyte count 2×109/l, differential leucocyte count - neutro 82%, lympho 18%, platelet count − 59×109/l, and red cell indices were as follows: MCV 71.6 fL, MCH 21.6 pg/cell, MCHC 30.2 g/dl. Her reticulocyte count was 0.5%. Peripheral blood smear showed pancytopenia with moderate anisopoikilocytosis. Her total bilirubin was 4.2 mg/dl and serum ferritin was found to be 1720 μg/L. In view of pancytopenia and non-response to antimalarials, patient was treated in line of septicemia with piperacillin and tazobactam, and simultaneously a bone marrow biopsy was performed. Bone marrow biopsy subsequently revealed a hypercellular marrow with erythroid hyperplasia. Number of macrophages was increased with some showing ingested red cells (hemophagocytosis) within them. In view of fever, splenomegaly, pancytopenia, hemophagocytosis and hyperferritinemia, a diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made as per HLH 2004 diagnostic criteria. Bone marrow also revealed multifocal epithelial granulomas with caseation, pointing the etiology to that of disseminated tuberculosis. Patient expired before any anti-tuberculous treatment could be instituted. Causes of HLH are broadly malignancy, collagen diseases and infections. Though malignancy and collagen diseases are common causes in the Western countries, tuberculosis is an important cause in a tropical country like India. Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4105-4105 ◽  
Author(s):  
Zaher K. Otrock ◽  
Charles S. Eby

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare potentially fatal hyperinflammatory syndrome. There are familial forms (primary HLH), typically presenting in childhood, and sporadic forms (secondary HLH), often presenting in adults. Many cases of HLH are in response to infectious pathogens. While Epstein Barr virus, HIV, and bacterial infections are the dominant non malignancy related causes linked with HLH, there are scattered case reports of other uncommon pathogens associated with HLH. We describe the clinical and laboratory findings from a series of 5 cases of Ehrlichia-induced HLH. Methods: We have reviewed diagnoses of HLH in adolescents and adults treated at Barnes-Jewish Hospital in St. Louis from June 2001 through June 2014. The diagnosis of Ehrlichia was made by PCR testing on peripheral blood. HLH diagnosis was based on the 2004 Histiocyte Society Criteria for HLH. Five of the following 8 criteria should be met: 1) fever ≥ 38.50C; 2) splenomegaly; 3) cytopenia of two or three lines: ANC < 1 × 103/µL, hemoglobin < 9 g/dL, platelet count < 100 × 103/µL; 4) hypertriglyceridemia ≥ 265 mg/dL or hypofibrinogenemia ≤ 150 mg/dL; 5) hyperferritinemia ≥ 500 µg/L; 6) increased soluble IL-2 receptor ≥ 2,400 U/mL; 7) low/absent natural killer (NK) cell activity; and 8) pathology showing hemophagocytosis (bone marrow, spleen, or lymph nodes). Results: Among 77 confirmed HLH cases, we identified Ehrlichia chaffeensis to be the causative agent of secondary HLH in 5 cases. Table 1 summarizes the initial characteristics of patients. All patients were Caucasian with a median age of 52 years (range, 16-62). Four patients were female and one male. All patients presented during summer time. Four patients reported recent history of tick bites. All patients were febrile on presentation. Hyperferritinemia was striking and median peak ferritin was 10002 µg/L (range, 2863-85517). Bone marrow biopsy was performed on 4 patients, 3 of which showed hemophagocytosis. Two patients had neurologic symptoms and they tested positive for Ehrlichia chaffeensis on cerebrospinal fluid. Doxycycline was administered on day 2, 1, 3, 1, and 1 of admission (respectively for patients 1 through 5). In addition to doxycycline, Patient 1 received rifampin and dexamethasone, Patient 2 received methyprednisolone, and Patients 4 and 5 received dexamethasone. After a median follow up of 7.3 months (range, 1.7-35.8), all patients were alive and none had recurrence of HLH. We identified an additional 4 cases of Ehrlichia infection presenting with fever, cytopenia(s), and high ferritin. These patients fulfilled 4 of the HLH diagnostic criteria. Al patients responded to doxycycline. Conclusion: Ehrlichia can trigger HLH and should be on the differential diagnosis of critically ill patients presenting with fever and hyperferritinemia, especially during warm weather when tick bites are more likely in areas endemic with Ehrlichia. Although HLH is often fatal, the prognosis of Ehrlichia-induced HLH is quite good with early diagnosis and prompt initiation of treatment. Table 1. Initial characteristics of patients Characteristic Patient 1* Patient 2* Patient 3 Patient 4 Patient 5 Age (years) 52 47 59 16 62 Gender F F F F M Fever Y Y Y Y Y Splenomegaly N N N N Y ANC (× 103/µL) 0.1 12.1 0.6 0.4 3.9 Hemoglobin (g/dL) 7.9 8.6 10.6 11.9 8.8 Platelets (× 103/µL) 25 65 41 37 20 Triglycerides (mg/dL) 650 710 307 319 516 Fibrinogen (mg/dL) 173 178 N/A 187 312 Ferritin (µg/L) 47290 10002 2863 85517 84676 Hemophagocytosis^ Y N Y Y N/P Soluble IL-2 (U/mL) >6500 5873 N/P N/P N/P Low/absent NK cell activity Failed N/P N/P N/P N/P * CNS involvement with Ehrlichia ^ Patients 1, 2, 3 and 4 had bone marrow biopsy. Pathology testing was not performed on lymph node or spleen. Abbreviations: F, female; M, male, Y, yes; N, no; N/P, not performed; ANC, absolute neutrophil count Disclosures No relevant conflicts of interest to declare.


2021 ◽  
pp. 194187442110446
Author(s):  
Matthew R. Woodward ◽  
Margaret S. Ferris ◽  
Guillermo Rivell ◽  
Laura Malone ◽  
Tara M. Dutta ◽  
...  

We are writing to present an interesting and novel case from our practice of a patient who presented with altered mental status and a rapidly progressive paraplegia as well as high fevers and pancytopenia. A bone marrow biopsy was diagnostic of hemophagocytic lymphohistiocytosis (HLH) and MRI showed hemorrhagic encephalitis and spinal subarachnoid hemorrhage. This case demonstrates the diverse neurological symptoms with which HLH presents, including spinal cord pathology. The astute neurologist should consider this diagnosis in the appropriate clinical context and diagnosis may require imaging to the complete neuraxis.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5391-5391
Author(s):  
Ritika Walia ◽  
Theresa Sepulveda ◽  
Sharon Wretzel ◽  
Philip H Brandt

Objectives: Primary myelofibrosis is rare in pediatrics, often manifesting as persistent idiopathic thrombocytosis.Transitions from pediatric to adult medical care can be complicated by workup requiring invasive procedures. J.M., an 18-year-old healthy male, presented for excessive gingival bleeding after wisdom tooth extraction. Workup revealed persistent thrombocytosis to 1,165K, prompting a referral to hematology-oncology. A peripheral smear was notable for many platelets but normal RBC morphology. He had splenomegaly on abdominal ultrasound and a decreased von-Willebrand's activity to antigen ratio, suggesting acquired vWD. A bone marrow biopsy was advised; however, J.M. became lost to follow up for over 9 months owing to self-reported anxiety about the procedure. He remained asymptomatic in this interim until he re-presented to clinic for easy bruising, with no other evidence of bleeding at the time. The biopsy was pursued, revealing hypercellular marrow for age with left shifted granulocytic and erythroid maturation, abnormal megakaryocytes, and 3% blasts. This was consistent with primary early myelofibrosis (PMF), positive for MF-1, CALR, and TP53 mutations and negative for JAK2 and BCR-ABL. He was transitioned to adult hematology, maintained on baby aspirin, and referred for potential allogeneic hematopoietic stem cell transplant (HSCT). PMF is characterized by marrow fibrosis due to secretion of fibroblast growth factor by clonally proliferative megakaryocytes. It is a disease of adulthood, with 67 years being the median age at diagnosis. Only 100 cases have been reported in children, most of which are secondary to AML, ALL or other malignancies.1 Most patients present with complications of extramedullary hematopoiesis or bleeding.2 Diagnosis is suggested by a leukoerythroblastic picture on peripheral smear and confirmed with a bone marrow biopsy "dry tap" revealing marrow fibrosis.3 Prognosis in pediatric PMF is difficult to predict but outcomes tend to be worse;4 TP53 mutation is rare and based on limited adult studies may portend a poorer prognosis.5 Our young patient with this rare mutation was therefore referred for HSCT evaluation. Further complicating this case was J.M.'s anxiety, which delayed definitive diagnosis by biopsy. He only agreed to it when, at the med-peds clinic, the concept of local pain management was discussed. Anticipation of upcoming procedures by primary care physicians and close follow-up is especially important for patients transitioning from pediatric to adult providers. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 34-35
Author(s):  
Manasi M. Godbole ◽  
Peter A. Kouides

Introduction: Most studies on the diagnostic yield of bone marrow biopsy including the one by Hot et al. have focused on the yield of bone marrow biopsies in diagnosing the source of fever of unknown origin. However, there have not been any studies performed to our knowledge looking at overall practice patterns and yield of bone marrow biopsies for diagnoses other than fever of unknown origin. We aim to determine the most common indications for performing bone marrow biopsies in a community-based teaching hospital as well as the yield of the biopsies in patients with specified and unspecified pre-test indications to estimate the rate of uncertain post-test diagnoses. Methods: We performed a retrospective data collection study at Rochester General Hospital, NY. A comprehensive search was conducted in our electronic medical data to identify all patients who underwent bone marrow biopsies over a 5 year period from January 2011 - December 2016 for indications other than fever of unknown origin. Patient data including demographics, pre-bone marrow biopsy diagnosis and post-bone marrow diagnosis was obtained. All patients above the age of 18 who underwent bone marrow biopsy for indications other than fever of unknown origin or follow up treatment of a hematological malignancy were included. Results: A total of 223 biopsies were performed. The median age was 59 years (age range- 23-95). One hundred and sixteen patients were male and 107 were female. The most common indications for performing bone marrow biopsy were evaluation of the following possible conditions: multiple myeloma (n=54), myelodysplastic syndrome [MDS] (n=47), lymphoma (n=28) and leukemia (n=18) as well as non-specific indications such as pancytopenia (n=40), anemia (n=22) and thrombocytopenia (n=11). The proportion of cases confirmed by bone marrow biopsy was 45/54 (83%) with the pre-marrow diagnosis of multiple myeloma, 34/47 cases (72%) with the pre-marrow diagnosis of MDS, 15/18 (83%) with the pre-marrow diagnosis of leukemia and 13/28 (46%) in those with the pre-marrow diagnosis of rule out lymphoma. Thirteen cases (18%) with possible MDS had post-bone marrow diagnoses of leukemia, anemia of chronic disease, myelofibrosis or medication-related changes. Five out of twenty two cases (23%) for anemia and 3/11 cases (27%) for thrombocytopenia without otherwise specified pre-bone marrow etiology had uncertain diagnosis after bone marrow biopsy. Conclusion: In about a fifth of patients necessitating a bone marrow, the diagnosis is discordant and can be surprising. It is also worth reporting that in these discordant results, non-hematological causes such as medications, anemia due to chronic diseases or conditions such as cirrhosis or splenomegaly from other etiologies were among the final diagnoses. Interestingly, 20% of the patients with unspecified pre-bone marrow diagnoses such as anemia or thrombocytopenia in our study had an unclear post-bone marrow diagnosis despite undergoing bone marrow biopsy. Our findings are a reminder that the bone marrow exam does not always lead to a definitive diagnosis and the need by exclusion to include in the differential non-hematological etiologies such as nutritional deficiencies, chronic kidney disease or autoimmune disorders. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4905-4905
Author(s):  
Hongxia Qiu ◽  
Meng Song ◽  
Fang Ni ◽  
Jujuan Wang

Abstract Abstract Objective: To analyze the epidemic characters, pathogenesis, clinical manifestations, laboratory data, therapeutic response, and prognosis in patients with staphylococcus septicemia-associated hemophagocytic lymphohistiocytosis(HLH). Methods A r Objective To analyze the epidemic characters, pathogenesis, clinical manifestations, laboratory data, therapeutic response, and prognosis in patients with staphylococcus septicemia-associated hemophagocytic lymphohistiocytosis(HLH). Methods: retrospective study was performed on 7 patients with staphylococcus septicemia-associated HLH who were admitted to The First Affiliated Hospital of Nanjing Medical University from January 2010 to December 2014. Results Seven out of 633patients(1.11%) with staphylococcus septicemia were confirmed to have HLH. The incidence of HLH in staphylococcus subspecies were:S.caprae, 12.50%;S.warneri, 12.50%;Methicillin-resistant Staphylococcusaureus(MRSA), 3.23%;S.hominis, 1.40%;S.haemolyticus, 1.25%;S.epidermidis, 0.59%, respectively. The main clinical manifestations included persistentfever(100%) and splenomegaly(85.71%). The most prominent laboratory abnormalities werehemocytopenia, abnormal hepatic function, and elevated ferritin. Bone marrow aspirations were performed on 6 patients and all of them hadhemophagocytosis shown in bone marrow smears. Among 7 patients, 4 patientssurvived(57.14%) and 3 patients died(42.86%). All the 4 cured patients were treated with antibiotic plus corticosteroid. And 2 of them used gamma globulin, while one used the COP chemotherapy regimen. Treatment with antibiotic plus corticosteroid was effective in our study. Conclusion Treatment with antibiotic plus corticosteroid was recommended for staphylococcus septicemia-associated HLH, and gamma globulin may also be useful in reducing the risk of death. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5966-5966
Author(s):  
Aishwarya Ravindran ◽  
Ronald S. Go ◽  
Kaaren K. Reichard ◽  
Ariela L. Marshall

Abstract BACKGROUND: Thrombocytopenia is a common hematologic condition associated with multiple etiologies ranging from benign to malignant to potentially life-threatening disorders. Given the heterogeneity of clinical presentations, available clinical information, and pertinent clinical history, there are inter-physician variations in the approach to the workup of thrombocytopenia in the hematology clinic. While a limited test repertoire may be adequate for many cases, more extensive testing may be warranted in others. We were interested in analyzing the various tests performed and testing approaches in the initial workup of thrombocytopenia. METHODS: We reviewed the records of 69 patients who were referred to our center between 2010 and 2015 for an initial workup of thrombocytopenia. We collected epidemiologic data, laboratory testing results, and pathologic findings. Pathologic results were classified as "normal" or "abnormal" and further subcategorized on the basis of review by two clinicians. Quantitative data were analyzed using JMP Pro 10.0.2 software. RESULTS: At the time of thrombocytopenia diagnosis, the median age was 59 years (range: 17-90) and majority were males (65%). The median platelet count was 91,000/µL (range: 3,000-146,000). Isolated thrombocytopenia was present in 51 cases (74%). Forty-four patients (64%) had a peripheral blood smear review and 4 (9%) contained abnormalities including hypogranular neutrophils, rouleaux formation, and target cells. Autoimmune workup included anti-platelet antibody (APA) in 34 (49%), anti-nuclear antibody (ANA) in 21 (30%), lupus anticoagulant (LA) in 4 (6%) and rheumatoid factor (RF) in 13 (19%) of cases. Autoimmune testing was positive for APA in 2 (5.9%), ANA in 4 (19%), LA in 0 (0%), and RF in 1 (8%) of patients who underwent testing, respectively. Common infectious workups included human immunodeficiency virus in 23 (33%), hepatitis A virus in 2 (3%), hepatitis B virus in 11 (16%), hepatitis C virus in 22 (32%), Epstein-Barr virus in 5 (EBV, 7%), cytomegalovirus in 7 (10%) and Helicobacter pylori in 5 (7%) of patients, and were negative in all cases except for one patient with evidence of active EBV infection. Sixteen patients (23%) underwent bone marrow biopsy, and 2 (12.5%) were diagnosed with hematologic malignancies including myelodysplastic syndrome and hairy cell leukemia. Based on results of these tests, 28 (41%) patients were diagnosed with primary immune thrombocytopenia, 19 (27%) with thrombocytopenia secondary to another medical condition, and 22 (32%) with thrombocytopenia of undefined etiology. CONCLUSION: Thrombocytopenia is a common laboratory finding, and workup involves significant inter-clinician variation, often involving multiple laboratory tests and in some cases invasive tests such as bone marrow biopsy. We found that autoimmune causes of thrombocytopenia were moderately common and infectious and malignant causes were rare. Our findings were based on a small cohort of patients but are likely to be representative of the clinical practice in a large tertiary care center. Large scale studies may be warranted to devise a protocol for a thorough yet cost-effective and stepwise initial workup of thrombocytopenia and to minimize unwarranted inter-clinician variation in such investigations. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5009-5009
Author(s):  
Rudolf Weide ◽  
Stefan Feiten ◽  
Vera Friesenhahn ◽  
Jochen Heymanns ◽  
Kristina Kleboth ◽  
...  

Abstract Introduction: New treatment options like thrombopoietin receptor agonists (TRAs) and rituximab have been introduced into the clinic which have found their way into national and international treatment guidelines. The aim of this study was to answer the following questions concerning diagnosis and treatment of patients with ITP in routine care: How are patients diagnosed and treated?Which sequences of therapy are applied?How many patients die due to bleeding complications? Methods: All patients with ITP diagnosed between 06/1995-06/2014 in a community-based oncology group practice in Germany were analyzed retrospectively. Results: 402 patients with a median age of 55 (7-90) were evaluated. 57% were female and 43% male. 357 (89%) were classified as primary ITP and 311 (77%) as having chronic ITP. In 234 patients (58%) a bone marrow biopsy was part of the diagnostic work up. Only 191 patients (48%) needed therapy. First line therapy (n=191) were steroids in 81%, intravenous immunoglobulins (ivIgG) in 12% and ivIgG plus steroids in 6%. Second line therapy (n=102) were ivIgG in 49%, steroids in 23%, ivIgG plus steroids in 17%, other immunosuppressive agents in 11% and splenectomy in 5%. Third line therapy (n=63) was splenectomy in 22%, other immunosuppressive agents in 27%, steroids in 19%, ivIgG in 16%, 11% combination therapy, rituximab in 10% and TRAs in 5%. Fourth line therapy (n=38) consisted of steroids in 26%, splenectomy in 26%, immunosuppressive agents in 34%, ivIgG in 13%, rituximab in 11% and TRAs in 3%. Patients received a median of 2 lines (1-10) of therapy. Treatment modalities most frequently used were steroids in 93%, immunoglobulins in 56%, splenectomy in 21% and other immunosuppressive agents in 21% of patients. Rituximab and TRAs were used in 10% and 5% only. 75% of patients received a durable remission (complete or partial) after their last therapy. 10% showed no response, in 15% remission couldn't be evaluated due to external treatments. 146 patients (76%) are off treatment. 1 patient (0.2%) died due to bleeding complications. Conclusions: Bone marrow biopsy is used as a diagnostic procedure in 58% of patients. Treatment modalities most frequently used are steroids, immunoglobulins, splenectomy and other immunosuppressive agents. Rituximab and TRAs are used infrequently. A high percentage of ITP-patients achieve durable remissions and ITP-related mortality is low. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4963-4963
Author(s):  
Jesus C Fabregas ◽  
Guiset Carvajal

Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by overwhelming activation of the immune system. The disease can affect patients of all ages and many times it goes under recognized for long periods of time, thus increasing its mortality due to organ failure. It mainly affects infants, nonetheless, adults can suffer from the disease as well, with catastrophic consequences. HLH etiology subsumes sporadic and familial presentations. Of the former, the two more common causes are infectious and neoplastic conditions. Clinical presentation includes nonspecific findings such as jaundice, hepatosplenomegaly, fever, fatigue, neurologic deficits. Laboratory findings display a spectrum of cytopenias, hemolysis, elevated ferritin, elevated IL-2, hypertriglyceridemia. Early initiation of treatment accounts for a great deal of the patient's recovery. Treatment consists of immunosuppressive therapy such as the HLH94 protocol - includes etoposide and dexamethasone -, or other combination immunosuppressive regimens. Using steroids alone is not typically a standard approach for the management of patients with HLH. Here we present a case of a patient with HLH with likely infectious etiology, successfully treated with steroids alone. Case Presentation A 34-year-old male patient presented to the emergency room (ER) complaining of jaundice, abdominal distention, fatigue, weakness, and fevers to 102 F. Vital signs were stable except for tachycardia hear rate 119 /min. Physical exam disclosed the presence of hepatosplenomegaly, palpable edge of liver, spleen palpable 6 cm below left costal margin, skin with jaundice. Blood work showed signs of cytopenias and hemolysis. WBC 2.2 /uL, hemoglobin 6.1 gr/dL, platelet count 114,000 /uL, neutrophil percentage 35%. On his peripheral smear review he had excessive monocytosis of 18%, atypical lymphocytes 31%, and 4% basophils. Reticulocyte count 1.3%. INR 1.2. AST elevated at 305 U/L, ALT 230 U/L, LDH 1063 U/L, Albumin 3.0 , total bilirubin 25.9, direct bilirubin 19.69, sodium 129. Haptoglobin less than 8. Coombs direct positive IgG subtype. Differential diagnosis included warm autoimmune hemolytic anemia. CT scan of the abdomen with contrast showed splenomegaly, 19.4 cm coronal view (fig 1), hepatomegaly as well, 21 cm in the mid hepatic craniocaudal diameter, steatosis. The patient was started on prednisone 1 mg/kg with rapid improvement on his laboratory parameters within the first 48 hours. A ferritin level on the third day of hospitalization was elevated at 2184. This finding along with unexplained transaminitis and hepatosplenomegaly raised suspicion for HLH. The patient met 6 out of the 8 criteria for diagnosis: Cytopenias (nadir ANC less than 1000, thrombocytopenia nadir 112,000, anemia), fever, splenomegaly, soluble CD25 (IL-2) elevated at 1803 pg/mL (normal values less than 1033 pg/mL), triglycerides 309 mg/dL, ferritin level 2184. Thus, the following workup was conducted. A. Bone marrow aspiration and biopsy showed hypercellular marrow with erythroid hyperplasia, negative for lymphoma or leukemia, adequate trilineage hematopoiesis (fig 2). B. Flow cytometry from peripheral blood was negative for paroxysmal nocturnal hemoglobinuria. C. PET-CT scan done negative for malignancy. D. Brain MRI: normal. E. Extensive infectious workup: the patient was found to have positive PCR, less than 2000 copies/mL, for Epstein-Barr virus. E. HLH gene panel was sent out showing negative results. F. Liver biopsy demonstrated extramedullary hematopoiesis. G. Reduced natural killer T cell cytotoxicity; reduced perforin levels. The patients' hemolysis, cytopenias and hepatosplenomegaly rapidly improve after initiation of steroids. The patient continued on steroid regimen during 6 months on a taper. Conclusion HLH is a devastating disease that potentially culminates in multisystem organ failure if not appropriately treated. At the time of clinical suspicion of HLH, approximately 3 days after the patient's admission, his clinical condition had improved on high dose steroids alone, therefore additional immunosuppression was not initiated. The patient might have had EBV that precipitated his HLH, however at the time of diagnosis his viral load was less than 2000 copies/mL and antiviral therapy was not considered necessary. He continues to be in remission, asymptomatic, 9 months after original diagnosis. Figure. Figure. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 5153-5153
Author(s):  
Getinet D. Ayalew ◽  
Juhi Mittal ◽  
Ratesh Khillan ◽  
Miriam Kim ◽  
Albert S. Braverman ◽  
...  

Abstract Abstract 5153 Introduction: Iron deficiency suppresses hemoglobin synthesis and erythropoiesis, but the resulting anemia is frequently associated with thrombocytosis. Methods: The clinical and hematologic data of seven women with severe iron deficiency anemia (IDA) and thrombocytopenia were retrospectively analyzed. Results: All patients were African-American women with symptomatic IDA, due to bleeding from uterine fibroids in 6 and from colonic diverticulosis in 1. They were 31–70 years of age, median 38. None had palpable splenomegaly. Hemoglobin ranged from 2.9–5.5, median 4.2 g/dL. MCV ranged from 57–70 fl, median 68. Absolute reticulocyte counts ranged from 19,000 – 23, 000/mm3. The initial serum ferritin ranged from 2 to 42 ng/ml, median 4. Serum iron levels ranged from 10 to 70 mcg/dl with median 30, while iron-binding capacities ranged from 381–426 mcg/dl. Serum erythropoietin (EPO) levels were >2000U/ml in two of the patients. Serum lactic dehydrogenase, bilirubin levels and liver function tests were normal; and Coombs' test negative in all cases. White blood cell counts were normal. The platelet counts ranged from 12 to 103, with a median of 46 × 109/L. Peripheral blood smears showed microcytic hypochromic red blood cells (RBC), with no evidence of platelet clumping. Bone marrow aspiration and biopsy on two patients showed increased numbers of normal megakaryocytes, erythroid hyperplasia and absent iron stores. Six patients were treated with packed RBC transfusions, and ferrous sulphate 325 mg orally was initiated at presentation in 7. Their thrombocytopenia was not treated with steroids or other agents. Three patients' platelet count reached normal or super-normal levels within 72 hours. Six patients were seen at ≥3 months after presentation, and all had achieved normal platelet counts and hemoglobin. Conclusions: These data imply that severe IDA can sometimes cause thrombocytopenia rather than thromobocytosis. We cannot be sure whether these patients' uniform normalization of platelet counts was due to treatment of their anemia by transfusion, or iron therapy. Though bone marrow megakaryocyte numbers were increased in 2 patients, there is no evidence for peripheral platelet destruction. Platelet release from megakaryocytes may have decreased in these patients. Pharmacologic EPO therapy can occasionally cause thrombocytopenia, and high endogenous EPO levels in our patients may have reduce their platelet counts. This conclusion is consistent with their apparent response to transfusion. Though the pathogenesis of IDA-associated thrombocytopenia is not known, our data suggest that the results of anemia and iron deficiency treatment should be evaluated before investigating thrombocytopenia as an independent problem. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2640-2640
Author(s):  
Andrew D Zelenetz ◽  
Jocelyn Maragulia ◽  
Steven M. Horwitz

Abstract Abstract 2640 BACKGROUND: The revised response criteria for malignant lymphoma (Cheson et al JCO 25:579 2007) incorporated FDG PET for determination of response. This was strongly recommended for patients with curable lymphomas (diffuse large B-cell lymphoma [DLBCL] and Hodgkin lymphoma [HL]). For incurable lymphomas PET was not recommended unless response was a major trial endpoint. Part of the reservation regarding the use of PET for response evaluation in incurable lymphomas was based on the potential variability in FDG avidity at baseline. This retrospective review was performed to understand the frequency of FDG avidity across a range of lymphoma histologies and compare diagnostic yield to CT. Furthermore, diagnostic utility of bone marrow biopsy was evaluated in patents with DLBCL and HL compared to identification of disease by FDG PET and CT scan. METHODS: After obtaining a waiver of authorization from the MSKCC Institutional Review Board patients the DAVInCI data mining tool was used to retrospectively identify patients with the diagnosis of lymphoma who had both a FDG-PET scan and CT at diagnosis available in the PACS. Either the FDG-PET or the CT had to be informative (which excluded patient with CS I resected disease). The sites of disease were recorded for PET (including SUVs) and for CT. The impact on the CS at diagnosis was determined. DLBCL and HL patients with bone (B) or bone marrow (BM) involvement were identified by being positive on any one modality: BM biopsy; FDG-PET; or CT. RESULTS: Data, including imaging, from 522 incident cases of lymphoma were reviewed. FDG PET performed for lymphoma at initial diagnosis demonstrated FDG-avid disease in 97.3% (508/522) of cases; there was some variability across histologies (Table 1). There was a strong correlation between CT and PET. PET identified more disease in 0–32.3% of cases depending on histology and CT was more informative in 3.2–33.3% of cases. CT tended to be more informative where the median SUV of PET was relatively low (SLL, MZL, MCL). The impact of FDG PET on Ann Arbor stage was modest but was greatest for SLL and T-cell lymphoma (Table 1, Change Stage). Identification of bone (B) and bone marrow (BM) disease in HL and DLBCL was examined. 57 patients with DLBCL were found to have B/BM involvement by BM, CT, or PET. PET was the most sensitive test for B/BM disease (50/57 88%). CT identified bone disease in 33/37 (58%) of cases but these were strictly a subset of the PET positive cases. However, BM biopsy identified involvement in 7 (15.2%) cases which were negative by PET. For HL, 20 patients were found to have B/BM disease. FDG PET identified all 20 cases, CT 12 cases and BM biopsy only 3. CONCLUSIONS: FDG-PET is positive in baseline in 97% of cases of lymphoma across all histologies. However, there is discordance between CT and PET in 28% of cases. Therefore, for clinical trials baseline contrast enhanced CT and FDG-PET are both necessary at baseline to full identify sites of disease. Outside the setting of a clinical trial, clinical discretion should be used in choosing the appropriate pre-treatment imaging. In the case of B/BM disease FDG-PET was the most informative modality in DLBCL and HL. However, bone marrow biopsy remains an essential part of the diagnostic evaluation of DLBCL since 7/20 bone marrow positive cases were not identified on FDG-PET or CT. The utility of the bone marrow biopsy in HL was questionable as FDG PET identified all cases of B/BM disease. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document